Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald

Neos Therapeutics (NASDAQ:NEOS) has been given a $20.00 price objective by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 93.24% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Cowen reiterated a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. BidaskClub upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Finally, Wells Fargo & Co set a $14.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. Neos Therapeutics has an average rating of “Hold” and a consensus target price of $14.00.

Neos Therapeutics (NEOS) traded down $0.10 during midday trading on Monday, hitting $10.35. 278,100 shares of the company traded hands, compared to its average volume of 358,350. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42. The company has a market cap of $299.39 and a price-to-earnings ratio of -3.03. Neos Therapeutics has a 1 year low of $4.85 and a 1 year high of $13.15.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.22. The firm had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. analysts anticipate that Neos Therapeutics will post -2.87 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. TIAA CREF Investment Management LLC increased its stake in Neos Therapeutics by 4.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock valued at $342,000 after purchasing an additional 2,168 shares in the last quarter. Rhumbline Advisers increased its stake in Neos Therapeutics by 13.6% during the 2nd quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares in the last quarter. California State Teachers Retirement System increased its stake in Neos Therapeutics by 14.1% during the 3rd quarter. California State Teachers Retirement System now owns 38,915 shares of the company’s stock valued at $356,000 after purchasing an additional 4,800 shares in the last quarter. Wells Fargo & Company MN increased its stake in Neos Therapeutics by 13.0% during the 2nd quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after purchasing an additional 6,223 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Neos Therapeutics by 67.3% during the 3rd quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors and hedge funds own 45.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/08/neos-therapeutics-neos-pt-set-at-20-00-by-cantor-fitzgerald.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

What are top analysts saying about Neos Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neos Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit